secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001193125-25-221756
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Climb Bio reports CLYM116 preclinical data showing >70% IgA reduction and longer half-life vs sibeprenlimab
--------------------------------------------------------------------------------

- In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.
- Subcutaneous CLYM116 demonstrated ~85% bioavailability and favorable tolerability in the NHP study.
- CLYM116 Phase 1 trial in healthy volunteers expected to start Q4 2025 with initial data mid-2026.
- CLYM116 is the only known 'sweeper' anti-APRIL monoclonal antibody in development for IgA nephropathy.
- Updated KDIGO 2025 guideline highlights need for more active IgAN management, expanding potential market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/0001193125-25-221756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525221756/d942245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-221756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer